Wealth Alliance Sells 26 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wealth Alliance reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 613 shares of the biopharmaceutical company’s stock after selling 26 shares during the quarter. Wealth Alliance’s holdings in Regeneron Pharmaceuticals were worth $538,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Sutton Wealth Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares in the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $40,000. 83.31% of the stock is owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock valued at $13,124,641 over the last ninety days. 8.83% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on REGN shares. Bank of America boosted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 12th. Barclays lifted their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Finally, BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $970.57.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $901.19 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The business’s 50 day moving average price is $955.19 and its two-hundred day moving average price is $890.52. The firm has a market cap of $98.91 billion, a PE ratio of 25.93, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the previous year, the firm earned $10.96 earnings per share. The company’s revenue was up .6% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.58 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.